Cell Signaling Technology

Product Pathways - Apoptosis / Autophagy

DR3 Antibody #3254

Applications Reactivity Sensitivity MW (kDa) Source
W H Endogenous 48 Rabbit

Applications Key:  W=Western Blotting
Reactivity Key:  H=Human
Species cross-reactivity is determined by Western blot.

Specificity / Sensitivity

DR3 Antibody detects endogenous levels of human DR3. It is not expected to cross-react with other TNF receptor family members.

Source / Purification

DR3 Antibody is produced by immunizing rabbits with a synthetic peptide (KLH-coupled) corresponding to residues within the intracellular domain of human DR3. Antibodies were purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of extracts from various cell lines, using DR3 Antibody.

Background

The tumor necrosis factor receptor family, which includes TNF-RI, Fas, DR3, DR4, DR5 and DR6, plays an important role in the regulation of apoptosis in various physiological systems (1,2). The receptors are activated by a family of cytokines that include TNF, FasL and TRAIL. They are characterized by a highly conserved extracellular region containing cysteine-rich repeats and a conserved intracellular region of about 80 amino acids termed the death domain (DD). The DD is important for transducing the death signal by recruiting other DD containing adaptor proteins (FADD, TRADD, RIP) to the death-inducing signaling complex (DISC) resulting in activation of caspases.

DR3/WSL-1/Apo-3/TRAMP/LARD is a TNFR family member containing the characteristic extracellular cysteine-repeats, transmembrane region, and intracellular DD (3-7). DR3 is activated by its ligand Apo-3L/TWEAK to induce apoptosis and activation of NF-κB (8,9). Like TNF-R1, DR3 binds to the DD adaptor protein TRADD, which can then associate with other DD proteins like FADD and RIP as well as members of the TRAF family (3,4). Tissue expression of DR3 is very restricted, primarily seen on the surface of activated thymocytes and lymphocytes and plays an important role in thymocyte negative selection (3,4,10). Studies have also indicated an association with DR3 and rheumatoid arthritis (11,12).

  1. Nagata, S. (1997) Cell 88, 355-365.
  2. Thorburn, A. (2004) Cell. Signal. 16, 139-144.
  3. Chinnaiyan, A.M. et al. (1996) Science 274, 990-992.
  4. Kitson, J. et al. (1996) Nature 384, 372-375.
  5. Marsters, S.A. et al. (1996) Curr. Biol. 6, 1669-1676.
  6. Bodmer, J.L. et al. (1997) Immunity 6, 79-88.
  7. Screaton, G.R. et al. (1997) Proc. Natl. Acad. Sci. USA 94, 4615-4619.
  8. Marsters, S.A. et al. (1998) Curr. Biol. 8, 525-528.
  9. Kaptein, A. et al. (2000) FEBS Lett. 485, 135-141.
  10. Wang, E.C. et al. (2001) Mol. Cell Biol. 21, 3451-3461.
  11. Osawa, K. et al. (2004) Genes Immun. 5, 439-443.
  12. Borysenko, C.W. et al. (2005) Biochem. Biophys. Res. Commun. 328, 794-799.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

This product is for in vitro research use only and is not intended for use in humans or animals. This product is not intended for use as therapeutic or in diagnostic procedures.

Product Pathways

Drug Discovery Tools

Featured Technologies

Protein Classes